Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	23.79B -15.8%
Revenue (ttm)	15.57B +30.2%
Net Income	1.46B +74.1%
EPS	6.31 +74.1%
Shares Out	231.00M
PE Ratio	16.33
Forward PE	n/a
Dividend	2.10 (2.04%)
Ex-Dividend Date	Nov 17, 2025

Volume	107,014
Open	104.30
Previous Close	103.80
Day's Range	102.80 - 105.80
52-Week Range	93.20 - 127.70
Beta	-0.11
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 22, 2026

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories such as oncology, hematology, anti-cancer, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointestin...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,771
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In fiscal year 2025, Beacon Pharmaceuticals's revenue was 12.54 billion, an increase of 17.20% compared to the previous year's 10.70 billion. Earnings were 946.51 million, an increase of 81.67%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 25, 2026

Data Sources Report a data error